HEP DART 2021

Hilton Los Cabos, Mexico / 5-9 December 2021

Dear Colleague,

Since its inception in 1995, HEP DART has established itself as an internationally recognized biennial conference that provides an important platform for scientists, healthcare workers, and clinicians to share and discuss the latest advancements in the field of viral hepatitis and liver cancer. Although advances in antiviral drug development against viral hepatitis have seen many successes over the past three decades, many obstacles still remain. HEP DART 2021 addressed current roadblocks in the field of hepatology such as injectable and shorter treatment for HCV, new advancements in HBV cure strategies, vaccine development and treatment access. In addition to viral hepatitis, this year’s program included special sessions on liver disease such as nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), and hepatocellular carcinoma (HCC).

Through participation in a carefully designed scientific program, delegates were able to identify current treatment limitations, and this in turn will allow for the development of novel and innovative approaches to resolve current scientific and clinical challenges. Considering the growing number of therapeutic options available for HCV treatment, clinicians and health care professionals will benefit from the opportunity to discuss the latest data with their academic peers and stay informed on the latest discoveries for their clinical practice. HBV cure, treatment optimization, and vaccination strategy will also be at the forefront of discussions. HEP DART provided accredited Continuing Medical Education training for physicians, ensuring a lasting and positive public health impact on treatment of liver disease worldwide.

The program included plenary lectures, abstract and poster presentations, along with discussion & debate.

Program chair,

Raymond F. Schinazi, PhD, DSc

Emory University, USA